A better than expected recovery in the ex-COVID business made-up for the rapid decline in COVID-19 sales, therefore DiaSorin reported sales in line in Q2. Akin to peers, the Italian firm has also lowered its FY21 guidance, mainly due to lower demand for COVID-19 antigen tests, but, as hospital business returns to normalcy, management foresees a steady demand for non-COVID products. In the mid-term, new product launches and the recently-integrated Luminex business should drive momentum. More deta ....
02 Aug 2021
Like peers, DiaSorin also turns cautious with its full-year targets
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Like peers, DiaSorin also turns cautious with its full-year targets
- Published:
02 Aug 2021 -
Author:
Sumit Sayal | Anas PATEL -
Pages:
3
A better than expected recovery in the ex-COVID business made-up for the rapid decline in COVID-19 sales, therefore DiaSorin reported sales in line in Q2. Akin to peers, the Italian firm has also lowered its FY21 guidance, mainly due to lower demand for COVID-19 antigen tests, but, as hospital business returns to normalcy, management foresees a steady demand for non-COVID products. In the mid-term, new product launches and the recently-integrated Luminex business should drive momentum. More deta ....